Cart
sales@molnova.com
dencichine
CAS No. 5302-45-4
dencichine( β-ODAP | Dencichine | BRN-2259036 | Ox-Dapro )
Catalog No. M18743 CAS No. 5302-45-4
Dencichine is a neurotoxic agent. Dencichine is a haemostatic agent, the hemostatic effect relates to modulation of the coagulation system, platelet aggregation and fibrinolytic system.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 103 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 350 | In Stock |
|
| 50MG | 509 | In Stock |
|
| 100MG | 733 | In Stock |
|
| 200MG | 1004 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namedencichine
-
NoteResearch use only, not for human use.
-
Brief DescriptionDencichine is a neurotoxic agent. Dencichine is a haemostatic agent, the hemostatic effect relates to modulation of the coagulation system, platelet aggregation and fibrinolytic system.
-
DescriptionDencichin, also known as β-ODAP, has been shown to alleviate metabolism disorder, improve renal function, relieve pathological alterations in the glomerulus of diabetic neuropathy in rats, decrease extracellular matrix deposition and increase the ratio of matrix metalloproteinase (MMP)-9 to tissue inhibitor of metalloproteinase (TIMP)-1 both in vivo and in vitro.
-
In VitroDencichin (β-ODAP, 10 μM, 50 μM, 100 μM and 200 μM) increases HRE expression by 1.3±0.09, 2.5±0.07, 4.2±0.15 and 1.3±0.07 fold respectively compared to control. Dencichin has intermolecular interactions with PHD-2. Dencichin (10 μM, 100 μM, 1 mM) significantly inhibits cell proliferation and extracellular matrix (ECM) proteins accumulation of HBZY-1 cells, and reduces the secretion of collagen I (Col I), collagen IV (Col IV), and fibronectin (FN).
-
In VivoDencichin improves metabolism disorder in diabetic nephropathy (DN) secondary to type II diabetes mellitus (DM) model. Dencichin (80, 160 mg/kg/day, p.o.) significantly prevents the up-regulation of TCH, TG, LDL, and HbAlc and the down-regulation of HDL in DN rats induced by STZ injection. Dencichin also attenuates renal injury induced in the DN secondary to type II DM model. Dencichin alleviates pancreas damage in the STZ-induced DN model. Dencichin regulates protein expression in the TGF-β/Smad signalling pathway in STZ-induced DN models.
-
Synonymsβ-ODAP | Dencichine | BRN-2259036 | Ox-Dapro
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number5302-45-4
-
Formula Weight176.13
-
Molecular FormulaC5H8N2O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 5 mg/mL (28.39 mM)
-
SMILESC([C@@H](C(=O)O)N)NC(=O)C(=O)O
-
Chemical NameOxamic acid, (2-amino-2-carboxyethyl)-, L-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
SSK1
SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
-
Emprumapimod
Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
-
PAF (C16)
PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.
